Breast cancer (BC) is the 2nd most common cancer worldwide and the most frequent cancer type occurring in women. The disease is highly heterogeneous consisting of various subtypes; and therapy and prognosis varies dependent on the BC subtype. Unfortunately, the currently used methods for BC imaging have limitations and current treatments for metastatic disease are unfortunately not associated with cure. Within nuclear medicine peptide receptor-mediated imaging and therapy using radioligands is clinically successfully used for imaging and treatment of neuroendocrine tumors. Ideally the same ligand is used for both imaging and treatment, the so called theranostic approach. Next to neuroendocrine tumors, this imaging and therapy method is under investigation for imaging and treatment of other cancer types as well. Concerning BC, overexpression of targets for which suitable radiotracers are available have been described.
The aim of the studies described in this thesis was to investigate the application of these radiotracers for theranostic purposes in BC, with the ultimate goal of improving BC patient care. The main focus was on targeting the gastrin releasing peptide receptor (GRPR) and somatostatin receptor subtype 2 (SSTR2), and to a lesser extent c-x-c chemokine receptor 4 (CXCR4), with radiotracers for both imaging and treatment.
The thesis is divided in 4 parts: Part 1 gives an introduction on the relevant subjects and provides an overview of receptor-targeted nuclear imaging of BC, part 2 focusses on the clinical relevance of targeting GRPR, SSTR2 and CXCR4 and part 3 and part 4 are focussed on targeting of SSTR2 and GRPR, respectively. All studies described in this thesis were performed in a preclinical setting.

, , , , , ,
M. de Jong (Marion) , C.H.M. van Deurzen (Carolien) , J.W.M. Martens (John)
Erasmus University Rotterdam
hdl.handle.net/1765/95527
Department of Nuclear Medicine

Dalm, S. (2017, February 21). The Application of Radiotracers for Theranostic Use in Breast Cancer. Retrieved from http://hdl.handle.net/1765/95527